New Somatostatin-derived substances for the treatment of neuropathic pain and related disorders
Neuropathic pain is rather resistant
to conventional analgesics. Therefore, different approaches must be taken to treat neuropathic pain. One possibility is the use of agents acting at the level of the sensory nerve terminals themselves to inhibit the release of these pro-inflammatory/pronociceptive sensory neuropeptides. Such agents may form the basis for the development of a new group of anti-inflammatory and analgesic drugs. In this invention Somatostatin-derived substances were developed that can inhibit inflammation without accompanying endocrine side effects. Furthermore they exhibit satisfactory half life and bioavailability, especially after oral administration.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Sea slugs inspire highly stretchable biomedical sensor
USC Viterbi School of Engineering researcher Hangbo Zhao presents findings on highly stretchable and customizable microneedles for application in fields including neuroscience, tissue engineering, and wearable bioelectronics. The revolution in…
Twisting and binding matter waves with photons in a cavity
Precisely measuring the energy states of individual atoms has been a historical challenge for physicists due to atomic recoil. When an atom interacts with a photon, the atom “recoils” in…
Nanotubes, nanoparticles, and antibodies detect tiny amounts of fentanyl
New sensor is six orders of magnitude more sensitive than the next best thing. A research team at Pitt led by Alexander Star, a chemistry professor in the Kenneth P. Dietrich…
